Thelper is developing an ADC treatment directed at US28, a virus-derived marker broadly expressed in aggressive solid tumors. The approach aims to improve efficacy and reduce side effects by selectively targeting a viral marker absent from healthy tissue. The company is advancing a pre-IND development package that includes expansion into additional solid-tumor indications with in vivo validation. Planned work also includes pharmacokinetic and toxicology studies to support regulatory filing. Thelper describes the recent financing milestone as a key step in progressing its therapeutic program. Katja Vetvik is cited as founder and CEO in the company statement.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2025